Last reviewed · How we verify
Pentacel (DPTaP+Hib)
Pentacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, pertussis, tetanus, and Haemophilus influenzae type b (Hib) bacteria.
Pentacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, pertussis, tetanus, and Haemophilus influenzae type b (Hib) bacteria. Used for Active immunization against diphtheria, pertussis, tetanus, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | Pentacel (DPTaP+Hib) |
|---|---|
| Sponsor | The Hospital for Sick Children |
| Drug class | Combination vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated toxins from diphtheria and tetanus bacteria, acellular pertussis antigens, and Hib polysaccharide conjugate. These components trigger adaptive immune responses that generate protective antibodies and cellular immunity against these four pathogens, preventing infection and disease.
Approved indications
- Active immunization against diphtheria, pertussis, tetanus, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
- Loss of appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentacel (DPTaP+Hib) CI brief — competitive landscape report
- Pentacel (DPTaP+Hib) updates RSS · CI watch RSS
- The Hospital for Sick Children portfolio CI